Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- PMID: 26260996
- PMCID: PMC4641011
- DOI: 10.1038/pcan.2015.39
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Abstract
Background: Primary prostate cancers are infiltrated with programmed death-1 (PD-1) expressing CD8+ T-cells. However, in early clinical trials, men with metastatic castrate-resistant prostate cancer did not respond to PD-1 blockade as a monotherapy. One explanation for this unresponsiveness could be that prostate tumors generally do not express programmed death ligand-1 (PD-L1), the primary ligand for PD-1. However, lack of PD-L1 expression in prostate cancer would be surprising, given that phosphatase and tensin homolog (PTEN) loss is relatively common in prostate cancer and several studies have shown that PTEN loss correlates with PD-L1 upregulation--constituting a mechanism of innate immune resistance. This study tested whether prostate cancer cells were capable of expressing PD-L1, and whether the rare PD-L1 expression that occurs in human specimens correlates with PTEN loss.
Methods: Human prostate cancer cell lines were evaluated for PD-L1 expression and loss of PTEN by flow cytometry and western blotting, respectively. Immunohistochemical (IHC) staining for PTEN was correlated with PD-L1 IHC using a series of resected human prostate cancer samples.
Results: In vitro, many prostate cancer cell lines upregulated PD-L1 expression in response to inflammatory cytokines, consistent with adaptive immune resistance. In these cell lines, no association between PTEN loss and PD-L1 expression was apparent. In primary prostate tumors, PD-L1 expression was rare, and was not associated with PTEN loss.
Conclusions: These studies show that some prostate cancer cell lines are capable of expressing PD-L1. However, in human prostate cancer, PTEN loss is not associated with PD-L1 expression, arguing against innate immune resistance as a mechanism that mitigates antitumor immune responses in this disease.
Conflict of interest statement
The authors declare competing financial interests. Charles G. Drake has consulted for Amplimmune, Bristol Myers Squibb (BMS), Merck, and Roche-Genentech, all of whom have either anti-PD-1 or anti-PD-L1 reagents in various stages of clinical development. In addition, Drs. Anders and Drake have received sponsored research funding from BMS. The first author Dr. Allison M. Martin has no conflicts of interest to declare.
Figures
Similar articles
-
Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2764-2769. doi: 10.1016/j.bbrc.2018.08.037. Epub 2018 Aug 9. Biochem Biophys Res Commun. 2018. PMID: 30100056
-
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.J Immunother Cancer. 2016 Oct 18;4:65. doi: 10.1186/s40425-016-0163-8. eCollection 2016. J Immunother Cancer. 2016. PMID: 27777774 Free PMC article.
-
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.Int J Mol Sci. 2019 Oct 17;20(20):5138. doi: 10.3390/ijms20205138. Int J Mol Sci. 2019. PMID: 31627272 Free PMC article.
-
Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.Mol Biol Rep. 2022 Jul;49(7):6633-6645. doi: 10.1007/s11033-022-07246-y. Epub 2022 Mar 17. Mol Biol Rep. 2022. PMID: 35301651 Review.
-
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Oncotarget. 2017. PMID: 28402953 Free PMC article. Review.
Cited by
-
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.Cancer Immunol Immunother. 2024 Oct 3;73(12):255. doi: 10.1007/s00262-024-03837-9. Cancer Immunol Immunother. 2024. PMID: 39358663 Free PMC article.
-
Evidence of Programmed Death-Ligand 1 Expression in a Highly Inflammatory Prostate: A Literature Review and Our Experience.Cureus. 2024 Aug 25;16(8):e67726. doi: 10.7759/cureus.67726. eCollection 2024 Aug. Cureus. 2024. PMID: 39318940 Free PMC article. Review.
-
Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: New promising strategy to reinvigorate cancer therapy.Heliyon. 2024 Sep 3;10(18):e37376. doi: 10.1016/j.heliyon.2024.e37376. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309904 Free PMC article. Review.
-
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.J Transl Med. 2024 Aug 9;22(1):751. doi: 10.1186/s12967-024-05552-6. J Transl Med. 2024. PMID: 39123227 Free PMC article. Review.
-
Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.Nat Rev Urol. 2024 Oct;21(10):615-637. doi: 10.1038/s41585-024-00869-9. Epub 2024 Apr 16. Nat Rev Urol. 2024. PMID: 38627553 Review.
References
-
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. - PubMed
-
- Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology. 2008;8(6):467–477. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials